ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.

Research Grants 9 show all


$50K
1991

Patents 1,804show all

  • 504
    A61K - Preparations for medical, dental, or toilet purposes
  • 364
    C07K - Peptides
  • 146
    C07D - Heterocyclic compounds
  • 84
    Y02A - Technologies for adaptation to climate change
  • 70
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 58
    C12N - Microorganisms or enzymes
  • 30
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 23
    A01K - Animal husbandry
  • 18
    C12P - Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture
  • 17
    C07H - Sugars

Clinical Trials 31show all

11Phase 17Phase 27Phase 36Phase 1/Phase 2

SEC Filings show all


286
8-K

75
10-Q

21
10-K

Contact Information

830 Winter Street
Waltham, MA 02451-1477
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$55,000,000501-10002017-05-30Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2011-12-20$20,000,000Post Ipo EquityEli Lilly
2011-10-20$3,000,000Post Ipo Equity
2011-06-15$2,000,000Post Ipo Equity
2017-05-30$30,000,000Post Ipo Equity